Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Authors:
Corrado Girmenia Anna Maria Raiola Alfonso Piciocchi Alessandra Algarotti Marta Stanzani Laura Cudillo Clara Pecoraro Stefano Guidi Anna Paola Iori Barbara Montante Patrizia Chiusolo Edoardo Lanino Angelo Michele Carella Elisa Zucchetti Benedetto Bruno Giuseppe Irrera Francesca Patriarca Donatella Baronciani Maurizio Musso Arcangelo Prete Antonio Maria Risitano Domenico Russo Nicola Mordini Domenico Pastore Adriana Vacca Francesco Onida Sadia Falcioni Giovanni Pisapia Giuseppe Milone Daniele Vallisa Attilio Olivieri Alessandro Bonini Elio Castagnola Simona Sica Ignazio Majolino Alberto Bosi Alessandro Busca William Arcese Giuseppe Bandini Andrea Bacigalupo Alessandro Rambaldi Anna Locasciulli

Biol Blood Marrow Transplant 2014 Jun 14;20(6):872-80. Epub 2014 Mar 14.

Pediatrics and Pediatric Hematology Unit, Az. Osp. S.Camillo-Forlanini, Rome, Italy.

Epidemiologic investigation of invasive fungal diseases (IFDs) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be useful to identify subpopulations who might benefit from targeted treatment strategies. The Gruppo Italiano Trapianto Midollo Osseo (GITMO) prospectively registered data on 1858 consecutive patients undergoing allo-HSCT between 2008 and 2010. Logistic regression analysis was performed to identify risk factors for proven/probable IFD (PP-IFD) during the early (days 0 to 40), late (days 41 to 100), and very late (days 101 to 365) phases after allo-HSCT and to evaluate the impact of PP-IFDs on 1-year overall survival. The cumulative incidence of PP-IFDs was 5.1% at 40 days, 6.7% at 100 days, and 8.8% at 12 months post-transplantation. Multivariate analysis identified the following variables as associated with PP-IFDs: transplant from an unrelated volunteer donor or cord blood, active acute leukemia at the time of transplantation, and an IFD before transplantation in the early phase; transplant from an unrelated volunteer donor or cord blood and grade II-IV acute graft-versus-host disease (GVHD) in the late phase; and grade II-IV acute GVHD and extensive chronic GVHD in the very late phase. The risk for PP-IFD was significantly higher when acute GVHD was followed by chronic GVHD and when acute GVHD occurred in patients undergoing transplantation with grafts from other than matched related donors. The presence of PP-IFD was an independent factor in long-term survival (hazard ratio, 2.90; 95% confidence interval, 2.32 to 3.62; P < .0001). Our findings indicate that tailored prevention strategies may be useful in subpopulations at differing levels of risk for PP-IFDs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2014.03.004DOI Listing
June 2014

Publication Analysis

Top Keywords

acute gvhd
12
chronic gvhd
8
gvhd late
8
osseo gitmo
8
midollo osseo
8
italiano trapianto
8
trapianto midollo
8
ii-iv acute
8
grade ii-iv
8
unrelated volunteer
8
transplant unrelated
8
late days
8
volunteer donor
8
donor cord
8
patients undergoing
8
cord blood
8
gruppo italiano
8
late phase
8
fungal diseases
8
cell transplantation
8

Altmetric Statistics


Show full details
8 Total Shares
6 Tweets
6 Citations

Similar Publications

Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.

Authors:
Yasmina Mozo David Bueno Luisa Sisinni Alba Fernández-Arroyo Blanca Rosich Antonio Pérez Martínez María Isabel Benítez-Carabante Laura Alonso María Luz Uría Cristina Díaz de Heredia Carmen Mestre-Duran Cristina Ferreras Bárbara Pascual Juan Torres Itsaso Losantos Adela Escudero Beatriz Ruz-Caracuel

Pediatr Hematol Oncol 2021 Mar 4:1-16. Epub 2021 Mar 4.

Translational Research in Pediatric Oncology, Hematopoietic Transplantation & Cell Therapy, Hospital La Paz Institute for Health Research (INGEMM-IdiPAZ), Institute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital, Madrid, Spain.

Ruxolitinib, a selective Janus Kinase (JAK) 1/2 inhibitor, is a promising treatment for the steroid-refractory graft-vs-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT). Most studies have been performed in the adult population showing efficacy against GvHD. In this retrospective study, we evaluated the outcomes of 19 children who received ruxolitinib for refractory acute or chronic GvHD (cGvHD) after HSCT from two Pediatric Hemato-Oncology Departments in Spain between March 2017 and December 2018. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation.

Authors:
Małgorzata Salamonowicz-Bodzioch Jowita Frączkiewicz Krzysztof Czyżewski Olga Zając-Spychała Ewa Gorczyńska Anna Panasiuk Marek Ussowicz Krzysztof Kałwak Zofia Szmit Grażyna Wróbel Bernarda Kazanowska Alicja Chybicka Bogna Ukielska-Hoffmann Danuta Wendycz-Domalewska Mariusz Wysocki Magdalena Dziedzic Jacek Wachowiak Agnieszka Zaucha-Prażmo Jerzy Kowalczyk Jolanta Goździk Jan Styczyński

Ann Hematol 2021 Mar 4. Epub 2021 Mar 4.

Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.

BK virus is one of the most common causes of hemorrhagic cystitis (HC) in children undergoing hematopoietic cell transplantation (HCT). Viruses can be found in urine and serum samples of immunocompromised patients. Malignant diseases, age, cell source, day of granulocyte reconstitution, conditioning regimen, or use of total body irradiation may play an important role in BKV epidemiology, development of hemorrhagic cystitis course, and outcome. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.

Authors:
Reid W Merryman Luca Castagna Laura Giordano Vincent T Ho Paolo Corradini Anna Guidetti Beatrice Casadei David A Bond Samantha Jaglowski Michael A Spinner Sally Arai Robert Lowsky Gunjan L Shah Miguel-Angel Perales Jean Marc Schiano De Colella Didier Blaise Alex F Herrera Geoffrey Shouse Chloe Spilleboudt Stephen M Ansell Yago Nieto Talha Badar Mehdi Hamadani Tatyana A Feldman Lori Dahncke Anurag K Singh Joseph P McGuirk Taiga Nishihori Julio Chavez Anthony V Serritella Justin Kline Mohamad Mohty Remy Dulery Aspasia Stamatoulas Roch Houot Guillaume Manson Marie-Pierre Moles-Moreau Corentin Orvain Kamal Bouabdallah Dipenkumar Modi Radhakrishnan Ramchandren Lazaros Lekakis Amer Beitinjaneh Matthew J Frigault Yi-Bin Chen Ryan C Lynch Stephen D Smith Uttam Rao Michael Byrne Jason T Romancik Jonathon B Cohen Sunita Nathan Tycel Phillips Robin M Joyce Maryam Rahimian Asad Bashey Hatcher J Ballard Jakub Svoboda Valter Torri Martina Sollini Chiara De Philippis Massimo Magagnoli Armando Santoro Philippe Armand Pier Luigi Zinzani Carmelo Carlo-Stella

Leukemia 2021 Mar 3. Epub 2021 Mar 3.

Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy.

Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may be associated with increased toxicity, raising challenging questions about the role, timing, and optimal method of transplantation in this setting. To address these questions, we assembled a retrospective cohort of 209 cHL patients who underwent alloHCT after PD-1 blockade. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

.

Authors:
Bárbara Betônico Berg Jaqueline Silva Soares Isabela Ribeiro Paiva Barbara Maximino Rezende Milene Alvarenga Rachid Stêfany Bruno de Assis Cau Thiago Roberto Lima Romero Vanessa Pinho Mauro Martins Teixeira Marina Gomes Miranda Castor

J Pharmacol Exp Ther 2021 Mar 3. Epub 2021 Mar 3.

Pharmacology, ICB/UFMG, Brazil

Cannabidiol (CBD) is a highly lipidic phytocannabinoid with remarkable anti-inflammatory effects. The aim of this study was to evaluate CBD's effects and mechanisms of action in the treatment of mice subjected to acute graft-versus-host disease (aGVHD). aGVHD was induced by the transplantation of bone marrow cells and splenocytes from C57BL-6j to Balb-c mice. Read More

View Article and Full-Text PDF
March 2021
Similar Publications

Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes.

Authors:
Najla El Jurdi Ahmad Rayes Margaret L MacMillan Shernan G Holtan Todd E DeFor Judith Witte Mukta Arora Jo-Anne Young Daniel J Weisdorf

Blood Adv 2021 Mar;5(5):1352-1359

Blood and Marrow Transplant Program.

Acute graft-versus-host disease (aGVHD) has various risk factors and outcomes. We defined distinct aGVHD treatment response groups based on response to first-line corticosteroids: steroid sensitive (SS), steroid resistant (SR), and the rarely studied steroid dependent (SD) aGVHD. In 1143 consecutive adult and pediatric allogeneic hematopoietic cell transplant recipients, 385 (34%) developed aGVHD, with 10% having SS aGVHD, 9% SD aGVHD, and 14% SR aGVHD. Read More

View Article and Full-Text PDF
March 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap